Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0361520050160020130
Korean Journal of Psychopharmacology
2005 Volume.16 No. 2 p.130 ~ p.138
Changes of Body Weight, Blood Glucose and Lipid Levels in Patients with Schizophrenia after Long-Term Clozapine Treatment
À̸íÁö
È«¼øÅÂ/¹èÀç³²/°­ÁÖÈñ/±èöÀÀ
Abstract
Objective£ºThis study was designed to investigate the effects of long term clozapine treatment on changes of weight, glucose and cholesterol levels and their relation to clozapine and its metabolite blood levels in outpatients with chronic schizophrenia. Methods£ºAmong outpatients diagnosed with schizophrenia according to the DSMIV criteria, 19 consented subjects receiving long-term treatment of clozapine, its dosage level had been constant for last one month, were selected for the study. The serum level of clozapine, metabolites as well as body weight, BMI, glucose level, cholesterol level, insulin, and c-peptide were gathered and analyzed before and after the use of clozapine. Results£ºGlucose increase after clozapine treatment was statistically meaningful but it was due to two patients who got diagnosed with diabetes. Glucose levels of other patients are all below 120 mg/dl. Cholesterol level showed significant increase after the treatment. Weight and BMI changes over the treatment are not statistically meaningful overall, but 8 out 17 showed more than 7% increase. The changes of weight and BMI were positively correlated with weight and BMI of pre treatment. Mean serum level of clozapine, metabolites were not correlated with glucose, cholesterol level, insulin, C-peptide.Conclusions£ºResults indicate that long term treatment of clozapine is correlated with increase of glucose and cholesterol level and weight gain of the patients. Clinicians should be aware of the potential risks of diabetes, hyperlipidemia, and weight gain in patients taking clozapine.
KEYWORD
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø